Why the study?
Does bivalirudin reduce infarct size compared with unfractionated heparin plus abciximab in STEMI patients undergoing primary PCI?
Does bivalirudin reduce infarct size compared with unfractionated heparin plus abciximab in STEMI patients undergoing primary PCI?
Bivalirudin does not significantly reduce infarct size or improve myocardial recovery compared to unfractionated heparin plus abciximab in STEMI patients undergoing primary PCI.
Answers are grounded in this paper and cite their sources.
Bivalirudin shows no infarct size benefit over heparin plus abciximab in STEMI primary PCI; confirms equivalent myocardial salvage with either regimen.
BACKGROUND: Myocardial infarct size is a strong independent predictor of mortality in patients with ST-elevation myocardial infarction (STEMI). In the Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial, bivalirudin compared with unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor reduced cardiac mortality in STEMI patients, which was attributed to reduced major bleeding. Whether a possible reduction in infarct size with bivalirudin may have contributed to the enhanced survival with this agent is unknown. METHODS: Cardiac magnetic resonance imaging was performed within 7 days and after 6 months in 51 randomized patients from a single center in HORIZONS-AMI trial (N = 28 bivalirudin, N = 23 heparin plus abciximab). Infarct size, microvascular obstruction (MVO), left ventricular ejection fraction (LVEF), and LV end-diastolic and end-systolic volume indices were evaluated. RESULTS: Infarct size was not significantly different after treatment with bivalirudin compared with heparin plus abciximab either within 7 days (median 9.3% [interquartile range 4.9%, 26.6%] vs. 20.0% [5.9%, 28.2%], P = 0.28) or at 6 months 6.7% [3.8%, 20.0%] vs. 8.2% [1.8%, 16.5%], P = 0.73). MVO was present in 28.6% versus 34.8% of patients respectively (P = 0.63). LVEF and LV volume indices also did not significantly differ between the two groups at either time period, nor were differences in myocardial recovery evident. CONCLUSIONS: In conclusion, in the HORIZONS-AMI Cardiac magnetic resonance imaging (CMRI) substudy, cardiac magnetic resonance imaging within 7 days and at 6 months after primary percutaneous coronary intervention (PCI) did not demonstrate significant differences in infarct size, MVO, LVEF, or LV volume indices in patients treated with bivalirudin compared with unfractionated heparin plus abciximab.
No takes yet. Share an insight, caveat, or question.
Wöhrle et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: